Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVSNovartis$145.48+0.6%$154.29$104.93▼$170.46$277.60B0.472.11 million shs1.33 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVSNovartis0.00%+1.72%-4.71%-2.11%+28.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVSNovartis$145.48+0.6%$154.29$104.93▼$170.46$277.60B0.472.11 million shs1.33 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVSNovartis0.00%+1.72%-4.71%-2.11%+28.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVSNovartis 2.31Hold$141.20-2.94% DownsideCurrent Analyst Ratings BreakdownLatest NVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026NVSNovartis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (A-) ➝ Buy (B)3/26/2026NVSNovartis Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$143.00 ➝ $170.003/19/2026NVSNovartis Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/11/2026NVSNovartis ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$180.002/17/2026NVSNovartis TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold2/12/2026NVSNovartis Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy2/9/2026NVSNovartis DZ BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold2/6/2026NVSNovartis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B) ➝ Buy (A-)2/5/2026NVSNovartis CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVSNovartis$56.58B4.91$10.66 per share13.65$22.04 per share6.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVSNovartis$13.98B$6.9820.8414.812.5624.87%38.82%15.16%7/21/2026 (Estimated)Latest NVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/28/2026Q1 2026NVSNovartis$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNVSNovartis$3.082.12%+5.28%44.13%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVSNovartis0.960.850.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipNVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVSNovartis75,2671.91 billion1.91 billionOptionableNVS HeadlinesRecent News About These CompaniesNew Bill: Representative Kathy Castor introduces H.R. 8651: Advancing Safe Medications for Moms and Babies Act of 2026May 5 at 11:51 AM | quiverquant.comQNovartis to cut 220 jobs as it closes German siteMay 5 at 8:16 AM | reuters.comQRG Capital Management Inc. Boosts Stock Holdings in Novartis AG $NVSMay 5 at 6:49 AM | marketbeat.comNovartis AG $NVS Shares Purchased by Truist Financial CorpMay 5 at 6:24 AM | marketbeat.comTriasima Portfolio Management inc. Acquires 32,620 Shares of Novartis AG $NVSMay 4 at 7:47 AM | marketbeat.comOppenheimer & Co. Inc. Reduces Position in Novartis AG $NVSMay 4 at 6:17 AM | marketbeat.comWilkins Investment Counsel Inc. Sells 17,565 Shares of Novartis AG $NVSMay 3 at 8:57 AM | marketbeat.comNovartis AG $NVS Shares Acquired by US Bancorp DEMay 1, 2026 | marketbeat.comErste Group Bank Raises Earnings Estimates for NovartisApril 30, 2026 | marketbeat.comNovartis AG $NVS Shares Sold by UBS Group AGApril 30, 2026 | marketbeat.comNovartis AG (NVS) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Core Income ...April 29, 2026 | finance.yahoo.comNovartis Expands R&D Spending Up To $70 Million Monthly After Avidity DealApril 29, 2026 | finance.yahoo.comErste Group Bank Weighs in on Novartis FY2026 EarningsApril 29, 2026 | marketbeat.comUK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policiesApril 29, 2026 | cnbc.comNovartis Q1 Earnings Call HighlightsApril 28, 2026 | marketbeat.comNovartis: Revenue Lags In Q1, Outlook UnchangedApril 28, 2026 | seekingalpha.comNovartis Q1 Earnings & Revenues Miss Estimates, Stock DownApril 28, 2026 | zacks.comNovartis (NVS) Stock Drops 2% After Q1 Revenue Miss and Entresto Sales Plunge 42%April 28, 2026 | blockonomi.comNovartis misses in Q1 but sticks with full-year outlookApril 28, 2026 | finance.yahoo.comNovartis Yo-Yoes As Generics Take A Bite Out Of Its First-Quarter SalesApril 28, 2026 | msn.comNovartis CEO flags risks from Trump's MFN drug policy as Q1 earnings miss estimatesApril 28, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVS Company DescriptionsNovartis NYSE:NVS$145.48 +0.86 (+0.59%) Closing price 03:59 PM EasternExtended Trading$145.67 +0.19 (+0.13%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
